Ambrx, Inc.

Idec Pharmaceuticals Corporation

Eli Lilly and Company

Biogen Idec, Inc.

Elanco US Inc.

Richard Spence Barnett

Feng Tian

Anna-Maria A Hays Putnam

Karen Retta McLachlan

Ying Sun

Stephanie Chu

Peter Connor Canning

Darin Lee

Joseph Sheffer

Kyle Atkinson

Marc Siladi

Frank Song

Mitchell R Reff

Nick Knudsen

Jason Pinkstaff

Amha Hewet

Sandra Biroc

Timothy Buss

Damien Bresson

Tsotne Javahishvili

Shailaja Srinagesh

Mitchell E Reff

Nickolas Knudsen

Andrew Beck

Marco Gymnopoulos

Jason K Pinkstaff

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

Anti-CD70 antibody drug conjugates

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are &#x3b1;CD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the &#x3b1;CD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.

This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are &#x3b1;PSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the &#x3b1;PSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.

Prostate-specific membrane antigen antibody drug conjugates

Modified animal erythropoietin polypeptides and uses thereof are provided.

Modified animal erythropoietin polypeptides and their uses

Modified animal erythropoietin polypeptides and uses thereof are provide.

A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetermined transcriptionally active site previously marked with a marker plasmid. The method is particularly suitable for the production of mammalian cell lines which secrete mammalian proteins at high levels, in particular immunoglobulins. Novel vectors and vector combinations for use in the subject cloning method are also provided.

Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Method for integrating genes at specific sites in mammalian cells via

Growing community of inventors

San Marcos, CA, United States of America

Richard Spence Barnett